Pharmaceutical Industry Articles & Reports - Page 18

Examine the technical and operational factors of CDMS replacement. Compare legacy SAS systems with modern cloud EDC platforms in clinical data management.

Learn how agentic AI in pharma transitions from pilot stages to production. Explore autonomous multi-agent systems, clinical use cases, and regulatory impacts.

Learn how Biobank LIMS software manages specimen tracking, chain-of-custody, and complex data architecture. Compare leading BIMS solutions for biorepositories.

Review how modern CTMS dashboards track clinical trial KPIs. This guide explains operational metrics for enrollment, site performance, and data management.

Examine why most pharma AI pilots fail to reach production. This report analyzes data fragmentation, governance issues, and building scalable data foundations.

A 2026 evaluation framework for selecting pharma AI consulting firms. Review vendor criteria including regulatory compliance, data governance, and AI expertise.

Explore the 2026 FDA-EMA 10 Guiding Principles of Good AI Practice in drug development. Learn about regulatory frameworks, compliance, and AI risk management.

Review a detailed 2026 commercial LIMS comparison. This report analyzes LabWare, STARLIMS, LabVantage, Sapio, and LabWizard features and deployment models.

Review how pharma data engineering workshops train teams in Databricks and AI. Examine Lakehouse architecture, GxP compliance, and workforce skills development.

Analyze IT integration in biopharma M&A. This report explains strategies for consolidating GxP systems, ensuring compliance, and capturing cost synergies.

An analysis of AI governance in pharmacovigilance, detailing how the EU AI Act and GxP regulations impact drug safety platforms like Oracle Argus and Veeva.

Compare open-source MES and ERP solutions for pharmaceutical manufacturing. Analyze ERPNext, Odoo, and others for GMP, 21 CFR Part 11, and Annex 11 compliance.

Review commercial software solutions for GMP-compliant manufacturing. Compare pharma MES, electronic batch records (eBR), and ERP systems for 21 CFR compliance.

Learn frameworks for GxP-safe AI. Covers RAG, audit trails, and data isolation to ensure 21 CFR Part 11 and Annex 11 compliance in pharma.

Review 10 years of FDA 483 patterns and EMA reports. Learn the four core inspection question clusters and the specific evidence required for compliance.

Learn about the impact of AI agents on B2B productivity in 2026. This analysis details enterprise adoption trends, case studies, and Anthropic's technical visio

Explore Project Orbis, the FDA's global oncology review framework. Analyze approval timelines, partner agencies, and challenges in expanding beyond cancer.

Explore Project Orbis, the FDA framework for simultaneous oncology drug review. Understand how international partners coordinate to reduce approval delays.

Examine Project Orbis data on FDA oncology approvals. Analysis shows concurrent review reduced submission gaps to 33 days and accelerated access by 2.6 months.

Analyze how FDA inspection delays and regulatory bottlenecks impact patient safety and drug supply. Learn how AI tools are addressing these critical backlogs.

Learn how FDA QMSR impacts 21 CFR 820. Internal audit and management review records are no longer confidential and subject to inspection under the new rule.

Analyze 2026 strategies for AI-assisted 510(k) submissions. Covers FDA guidance, generative AI tools, and mandatory human oversight protocols.

Analyze the FDA QMSR final rule, ISO 13485 alignment, and the new CP 7382.850 inspection playbook. Learn key compliance steps for device manufacturers.

Analyze FDA Project Elsa, a generative AI system that prioritizes facility inspections by detecting risk patterns in adverse events and regulatory data.